Ekso Bionics (EKSO) 10-Q2021 Q1 Quarterly report

Filed: 29 Apr 21, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: bore, caption, deducting, Europe, hopeful, interpretation, involuntary, leave, live, lock, onsite, pathogen, pipeline, PSU, recall, Reclassification, subscription, team, uptick, vaccinated

Removed: absence, accelerate, acceptable, adjust, affiliate, affiliated, agreed, amounting, analogy, Angel, application, applying, appointment, approved, authority, barrier, burn, Cantor, capitalized, Chief, China, collection, collectively, commensurate, commitment, Committee, comparability, complexity, conditional, consolidation, consulting, continued, Controlled, converted, curtail, deemed, delay, depend, determine, dilution, disclose, discretionary, doubt, Dr, effecting, entering, exchanged, exercising, expensed, expired, explanatory, expressing, favorable, FDA, file, firm, Fitzgerald, founder, Framework, globally, goodwill, implied, Incentive, increasing, independent, Intelligent, introduction, investment, joint, JV, large, larger, largest, leasing, licensing, LP, maintained, manage, manufacture, merger, met, mitigated, modification, NaN, national, nationally, nonreciprocal, obtained, OfferingSM, owe, paragraph, partner, patient, Pond, positioning, prepare, private, prohibited, Puissance, qualify, reciprocal, recognizable, referred, region, registered, regularly, removed, removing, reserve, resume, return, review, SEBD, SEDB, September, significantly, Simplifying, strategic, sublicense, substantial, Ted, Test, tooling, transition, transparency, trial, unable, unconditional, unconsolidated, underwritten, venture, Wang, workforce, Youchuang, Zhejiang

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EKSO transcripts

EKSO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

In connection with the Quarterly Report on Form 10-Q of Ekso Bionics Holdings, Inc. (the “Company”), for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Jack Peurach, President and Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: April 29, 2021


			/s/ Jack Peurach
			Jack Peurach
			Principal Executive Officer